The global Nucleic Acid Testing Market is expected to witness significant expansion over the next decade driven by the increased investments in molecular diagnostic systems, which offer fast and precise results. “According to a recent study by SNS Insider, the global Nucleic Acid Testing Market size valued at USD 4.52 billion in 2025, is anticipated to grow to USD 8.42 billion by 2035, registering a CAGR of 6.57% over the 2026–2035 forecast period.”
Increased demands for disease detection at an early stage, growing importance of precision medicine, and growing application of molecular diagnostics in infectious diseases, oncology, and genetics have created immense possibilities for players operating in the industry. Healthcare institutions are increasingly investing in testing systems that will help make fast decisions and deliver better results due to high-sensitivity molecular tests.
The continued expansion of genomic medicine, laboratory automation, and decentralized diagnostic services is further strengthening demand for next-generation molecular testing solutions across hospitals, clinical laboratories, and research institutions worldwide.
To Get Detailed Insights on the Nucleic Acid Testing Market – Request a Sample Report
Molecular Innovation Continues to Transform Modern Diagnostics
The advancement of technology is rapidly changing the molecular diagnostics industry via advancements in automation, digitization of laboratory processes, and new analytical technologies. The incorporation of integrated testing approaches in the healthcare industry is leading to increased efficiency, improved turnaround times, and an ability to perform more tests.
Advances in the use of artificial intelligence, cloud-based laboratory management tools, and sequencing technology are making diagnostics even more sophisticated and allowing health care providers to provide more personalized treatment protocols.
These developments are expected to expand the role of nucleic acid testing across routine clinical practice, public health surveillance, pharmaceutical research, and precision medicine initiatives.
Key Market Findings Highlight Emerging Growth Opportunities
By categories, reagents and kits accounted for 46.69% of global market revenue in 2025, reflecting consistent demand from diagnostic laboratories and healthcare facilities performing routine molecular testing. software and services are expected to register the fastest growth during the forecast period, supported by increasing laboratory digitization, workflow automation, and advanced data management requirements.
On the basis of technology, polymerase chain reaction (PCR) and real-time PCR represented 42.54% of total market revenue in 2025, maintaining their position as widely adopted molecular testing platforms across numerous clinical applications. At the same time, sequencing-based testing is projected to emerge as the fastest-growing technology segment, driven by expanding applications in precision medicine, oncology, and genomic research.
By application analysis, infectious disease diagnostics accounted for 39.44% of market revenue in 2025, highlighting continued demand for rapid pathogen detection and disease surveillance. However, oncology testing is expected to witness the strongest growth through 2035, supported by increasing utilization of biomarker-driven diagnostics and personalized cancer treatment strategies.
Based on end users, hospitals and diagnostic laboratories held 43.59% of global market revenue in 2025, while pharmaceutical and biotechnology companies are anticipated to record the fastest growth, reflecting increasing investments in drug development, biomarker discovery, and companion diagnostic technologies.
Precision Medicine and Decentralized Testing Drive Future Demand
Precision medicine programs for enhancing diagnostics, treatment choices, and managing patients have been adopted by many healthcare practitioners in the world. There has been an increasing need for molecular tests in order to facilitate personalized medicine.
Another factor that has been driving the growth in the demand for molecular diagnostics includes the demand for decentralization of diagnostic tests. This demand can be met through portable molecular diagnostics technology platforms which can provide results accurately.
Regional Markets Continue to Expand
North America contributed 38.49% to global market revenue in 2025 owing to well-developed molecular diagnostics infrastructure, investments in healthcare, and widespread use of technology in precision medicine. The region has been witnessing active research projects and involvement of various molecular diagnostics firms.
On the other hand, the Asia Pacific region is expected to witness the highest growth rate, registering a CAGR of 24.45% till 2035. There have been rapid developments in the healthcare sector, increasing investment in genomics, development of laboratory facilities, and the adoption of advanced molecular diagnostics technology in the region.
Leading Companies Continue to Advance Molecular Diagnostics
The competitive landscape remains dynamic as manufacturers continue investing in laboratory automation, advanced molecular platforms, artificial intelligence integration, and strategic collaborations aimed at strengthening diagnostic capabilities and expanding global market presence.
Key companies operating in the global nucleic acid testing market include Roche Diagnostics, QIAGEN, Abbott Laboratories, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Siemens Healthineers, bioMérieux, Illumina, and Agilent Technologies.
An SNS Insider analyst Parry Kardani commented, "The convergence of molecular diagnostics, genomics, laboratory automation, and precision medicine is transforming healthcare worldwide. Continued innovation in nucleic acid testing technologies will play a pivotal role in improving disease detection, accelerating clinical decision-making, and supporting the next generation of personalized healthcare."
About the Author
Get in touch
